FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      
1. Name and Address of Reporting Person * Masson-Hurlburt Elizabeth 2. Issuer Name and Ticker or Trading Symbol CorMedix Inc. [ CRMD ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
EVP, Head of Clinical Ops
(Last)         (First)         (Middle)
C/O CORMEDIX INC.,, 300 CONNELL DRIVE, SUITE 4200
3. Date of Earliest Transaction (MM/DD/YYYY)
5/21/2021
(Street)
BERKELEY HEIGHTS, NJ 07922
(City)       (State)       (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)
 
6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock  5/21/2021    S    8000  D $6.9242 (1) 0  D   

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy Common Stock)  $8.32                   (2) 1/11/2031  Common Stock  140000    140000  D   
Stock Option (Right to Buy Common Stock)  $5.63                   (3) 5/11/2030  Common Stock  37500    37500  D   
Stock Option (Right to Buy Common Stock)  $4.08                   (3) 5/11/2030  Common Stock  37500    37500  D   
Stock Option (Right to Buy Common Stock)  $5.63                   (4) 2/25/2030  Common Stock  24764    24764  D   
Stock Option (Right to Buy Common Stock)  $8.3                   (5) 1/10/2029  Common Stock  20880    20880  D   
Stock Option (Right to Buy Common Stock)  $1.45                   (6) 3/19/2028  Common Stock  54000    54000  D   

Explanation of Responses:
(1)  This transaction was executed in multiple trades at prices ranging from $6.665 to $6.97. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
(2)  These options were granted on 1/11/2021. These options vest, subject to continued employment, as follows: 50% of the options vest over time, with 25% vested on the grant date and 25% vesting in equal thirds on the first, second and third anniversaries of the grant date; and 50% of the options vest upon the achievement of certain milestones.
(3)  These options were granted on 05/11/2020. These options vest 1/4 on the date of grant, 1/4 on the first anniversary of the date of grant, 1/4 on the second anniversary of the date of grant and 1/4 on the third anniversary of the date of grant.
(4)  These options were granted on 02/25/2020. These options vest 1/4 on the date of grant, 1/4 on the first anniversary of the date of grant, 1/4 on the second anniversary of the date of grant and 1/4 on the third anniversary of the date of grant.
(5)  These options were granted on 1/10/2019. These options vest, subject to continued employment, as follows: 35% of the options vest over time, with 25% vested on the grant date and 25% vesting on the first, second and third anniversaries of the grant date; and 65% of the options vest upon the achievement of certain milestones. These options include options to purchase 2,100 shares that are subject to vesting each on January 10, 2021 and January 10, 2022.
(6)  The options vest as follows: 37,200 will vest over four years in four (4) equal installments on the first four anniversaries of 3/19/2018. The remaining options vest on the achievement of certain milestones, subject to continued employment.

Remarks:
The Issuer effected a 1-for-5 reverse stock split of its common stock on March 26, 2019. All share and per share exercise price amounts shown in this Form 4 have been adjusted to reflect the reverse stock split.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Masson-Hurlburt Elizabeth
C/O CORMEDIX INC.,
300 CONNELL DRIVE, SUITE 4200
BERKELEY HEIGHTS, NJ 07922


EVP, Head of Clinical Ops

Signatures
/s/ Elizabeth Masson-Hurlburt 5/25/2021
**Signature of Reporting Person Date
CorMedix (NASDAQ:CRMD)
Historical Stock Chart
From Aug 2021 to Sep 2021 Click Here for more CorMedix Charts.
CorMedix (NASDAQ:CRMD)
Historical Stock Chart
From Sep 2020 to Sep 2021 Click Here for more CorMedix Charts.